Gravity Analytica

Incyte to Spotlight New Data, Including a Late Breaking Oral Presentation for Tafasitamab in Follicular Lymphoma, at the 2024 ASH Annual Meeting

INCY 11.25.2024

SERA-AI Powered Highlights

Drug:tafasitamab-cxix Monjuvi

Drug:axatilimab-csfr Niktimvo

Drug:ruxolitinib Jakafi

Diseases:follicular lymphoma

Diseases:Chronic Graft-Versus-Host Disease

Diseases:Myeloproliferative Neoplasms

Date of Upcoming Event:2024-12-07

Name of Upcoming Event:2024 American Society of Hematology Annual Meeting

Full Press Release SEC Filings Our INCY Tweets

About Gravity Analytica

Recent Filings

PDF Version

-Twenty presentations, including late-breaking, oral and poster presentations, highlight advances across seven of the company’s medicines

-Late-breaking data presentation at ASH will feature results from the Phase 3 inMIND study evaluating tafasitamab in follicular lymphoma (FL); data to be highlighted during ASH press program

-Incyteto host virtual analyst and investor event onThursday, December 12, 2024, from4:00-5:00 p.m. ETto discuss key data presentations from ASH

WILMINGTON, Del.--(BUSINESS WIRE)--Nov. 25, 2024--Incyte(Nasdaq: INCY) today announced that the Company will present new data from across its oncology portfolio at the 2024American Society of Hematology(ASH) Annual Meeting inSan Diego.

“These data illustrate our innovative approach that aims to identify new and best-in-class treatments for patients with a range of cancers,” saidPablo J. Cagnoni, M.D.,Presidentand Head of Research and Development,Incyte. “At ASH, we’re presenting comprehensive data from our Phase 3 inMIND trial in relapsed or refractory follicular lymphoma. This late-breaking presentation provides valuable insights into the potential role of tafasitamab in improving outcomes for FL patients who currently face limited effective treatment options.”

Details on key abstracts accepted for presentation include:

ASH Abstracts

Late-Breaking Oral Presentation

TafasitamabTafasitamab Plus Lenalidomide and Rituximab for Relapsed or Refractory Follicular Lymphoma: Results from a Phase 3 Study (inMIND)Session: Late-Breaking Abstracts Session. Publication Number: LBA-1.December 10,10:30 a.m. ET(7:30 a.m. PT).

Oral Presentations

AxatilimabDynamics of Overall and Organ-Specific Responses to Axatilimab in Chronic Graft-Versus-Host Disease: Analysis from the AGAVE-201 StudySession: 722. Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution: Predicting and Treating Acute and Chronic GVHD. Publication Number: 98.December 7,12:45 p.m. ET(9:45 a.m. PT).

INCB057643Safety and Efficacy of Bromodomain and Extra-Terminal Inhibitor INCB057643 in Patients with Relapsed or Refractory Myelofibrosis and Other Advanced Myeloid Neoplasms: A Phase 1 StudySession: 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Advancing Treatment Paradigms in Myeloproliferative Neoplasms and Mastocytosis. Publication Number: 658.December 8,8:15 p.m. ET(5:15 p.m. PT).

Poster Presentations

Ruxolitinib (Myeloproliferative Neoplasms [MPN])Clinical and Molecular Characterization of Disease Progression in Patients (Pts) with Low-Risk Myelofibrosis (MF) Enrolled in the MOST StudyPoster Session: 631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Poster II. Publication Number: 3136.December 8,9:00 p.m.–11:00 p.m. ET. (6:00 p.m.–8:00 p.m. PT).

Molecular Predictors of Disease Progression to Myelofibrosis (MF) in Patients (Pts) with Polycythemia Vera (PV) Enrolled in REVEALPoster Session: 631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Poster II. Publication Number: 3145.December 8,9:00 p.m.–11:00 p.m. ET. (6:00 p.m.–8:00 p.m. PT).

Real-World Treatment Patterns and Blood Count Control in Patients with Polycythemia Vera Who Switched From Hydroxyurea to RuxolitinibPoster Session: 908.Outcomes Research: Myeloid Malignancies: Poster II. Publication Number: 3813.December 8,9:00 p.m.–11:00 p.m. ET. (6:00 p.m.–8:00 p.m. PT).

Clinical Outcomes in Patients with Myelofibrosis Treated with Ruxolitinib and Anemia-Supporting MedicationsPoster Session: 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster III. Publication Number: 4546.December 9,9:00 p.m.–11:00 p.m. ET. (6:00 p.m.–8:00 p.m. PT).

Ruxolitinib (Graft-versus-host Disease [GVHD])Real-World Ruxolitinib and Corticosteroid Treatment Patterns in Patients with Chronic Graft-Versus-Host Disease inthe United StatesPoster Session: 722. Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution: Poster III. Publication Number: 4900.December 9,9:00 p.m.–11:00 p.m. ET. (6:00 p.m.–8:00 p.m. PT).

TafasitamabReal-World Effectiveness of Tafasitamab (Tafa) for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) inthe United StatesPoster Session: 906.Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Poster I. Publication Number: 2375.December 7,8:30 p.m.–10:30 p.m. ET(5:30 p.m.–7:30 p.m. PT).

Maintenance of CD19 Expression After Tafasitamab Treatment in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) From Clinical Trial and Real-World SettingsPoster Session: 622. Lymphomas: Translational – Non-Genetic: Poster II. Publication Number: 2991.December 8,9:00 p.m.–11:00 p.m. ET. (6:00 p.m.–8:00 p.m. PT).

AxatilimabAxatilimab Abrogates Inflammatory Cytokines and Chemokines and Interrupts the Differentiation of Monocytes to Macrophages, a Pathogenic Driver of Inflammation and Fibrosis in cGVHDPoster Session: 201. Granulocytes, Monocytes, and Macrophages: Poster I. Publication Number: 1147.December 7,8:30 p.m.–10:30 p.m. ET(5:30 p.m.–7:30 p.m. PT).

Exposure-Response Relationships for Axatilimab, a Humanized Monoclonal Antibody Targeting CSF-1R, in Patients with Chronic Graft-Versus-Host DiseasePoster Session: 722. Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution: Poster I. Publication Number: 2140.December 7,8:30 p.m.–10:30 p.m. ET(5:30 p.m.–7:30 p.m. PT).

Real-World Patient Characteristics and Treatment Patterns in Patients with Chronic Graft-Versus-Host Disease Receiving Belumosudil inthe United StatesPoster Session: 722. Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution: Poster II. Publication Number: 3522.December 8,9:00 p.m.–11:00 p.m. ET. (6:00 p.m.–8:00 p.m. PT).

PonatinibThe Impact of Ponatinib on Pregnancy OutcomesPoster Session: 908.Outcomes Research: Myeloid Malignancies: Poster I. Publication Number: 2435.December 7,8:30 p.m.–10:30 p.m. ET(5:30 p.m.–7:30 p.m. PT).

Long-Term Safety and Effectiveness of Ponatinib Treatment in Patients with TKI Intolerance: Subgroup Analysis of the Observational Study of Ponatinib Treatment in Patients with CML inItaly(OITI)Poster Session: 908.Outcomes Research: Myeloid Malignancies: Poster I. Publication Number: 2427.December 7,8:30 p.m.–10:30 p.m. ET(5:30 p.m.–7:30 p.m. PT).

Ponatinib Safety Profile: An Analysis of 10-Years of Real-World ExperiencePoster Session: 908.Outcomes Research: Myeloid Malignancies: Poster II. Publication Number: 3816.December 8,9:00 p.m.–11:00 p.m. ET. (6:00 p.m.–8:00 p.m. PT).

INCB057643Machine Learning in Predicting Longitudinal Platelet Counts: Applications in Dose OptimizationPoster Session: 803. Emerging Tools, Techniques, and Artificial Intelligence in Hematology: Poster III. Publication Number: 4985.December 9,9:00 p.m.–11:00 p.m. ET. (6:00 p.m.–8:00 p.m. PT).

More information regarding the 2024 ASH Annual Meeting can be found on their website:https://www.hematology.org/meetings/annual-meeting/schedule-and-program.

All sessions will be broadcast virtually, and access to the meeting’s virtual platform is included with registration.

Conference Call and WebcastIncytewill hold a conference call and webcast onThursday, December 12, 2024, from4:00-5:00 p.m. ET, to discuss key data presentations at ASH, including data from the Phase 3 inMIND study presented during the late breaking session and itsBETinhibitor program.

To access the conference call, please dial 877-407-3042 for domestic callers or 201-389-0864 for international callers. When prompted, provide the conference identification number, 13750244.

If you are unable to participate, a replay of the conference call will be available for thirty days. The replay dial-in number forthe United Statesis 877-660-6853 and the dial-in number for international callers is 201-612-7415. To access the replay, you will need the conference identification number, 13750244.

The live webcast with slides can be accessed atInvestor.Incyte.comand will be available for replay for ninety days.

About Jakafi^®(ruxolitinib)Jakafi^®(ruxolitinib) is a JAK1/JAK2 inhibitor approved by theU.S.FDA for treatment of polycythemia vera (PV) in adults who have had an inadequate response to or are intolerant of hydroxyurea; intermediate or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF and post-essential thrombocythemia MF in adults; steroid-refractory acute GVHD in adult and pediatric patients 12 years and older; and chronic GVHD after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older.

Jakafi is a registered trademark ofIncyte.

About Monjuvi^®(tafasitamab-cxix)Monjuvi^®(tafasitamab-cxix) is a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody. In 2010, MorphoSys licensed exclusive worldwide rights to develop and commercialize tafasitamab from Xencor, Inc. Tafasitamab incorporates an XmAb^®engineered Fc domain, which mediates B-cell lysis through apoptosis and immune effector mechanism including Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) and Antibody-Dependent Cellular Phagocytosis (ADCP). MorphoSys andIncyteentered into: (a) inJanuary 2020, a collaboration and licensing agreement to develop and commercialize tafasitamab globally; and (b) inFebruary 2024, an agreement wherebyIncyteobtained exclusive rights to develop and commercialize tafasitamab globally.

Inthe United States, Monjuvi^®(tafasitamab-cxix) received accelerated approval by theU.S. Food and Drug Administrationin combination with lenalidomide for the treatment of adult patients with relapsed or refractory DLBCL not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant (ASCT). InEurope, Minjuvi^®(tafasitamab) received conditional Marketing Authorization from theEuropean Medicines Agencyin combination with lenalidomide, followed by Minjuvi monotherapy, for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant (ASCT).

XmAb^®is a registered trademark of Xencor, Inc.

Monjuvi, Minjuvi, the Minjuvi and Monjuvi logos and the “triangle” design are registered trademarks ofIncyte.

About Zynyz^®(retifanlimab-dlwr)Zynyz^®(retifanlimab-dlwr), is an intravenous PD-1 inhibitor indicated in theU.S.for the treatment of adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC). This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

Zynyz is marketed byIncytein theU.S.In 2017,Incyteentered into an exclusive collaboration and license agreement with MacroGenics, Inc. for global rights to retifanlimab.

Zynyz is a registered trademark ofIncyte.

About Pemazyre^®(pemigatinib)Pemazyre^®(pemigatinib) is a kinase inhibitor indicated inthe United Statesfor the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test*. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

Pemazyre is also the first targeted treatment approved for use inthe United Statesfor treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with FGFR1 rearrangement.

InJapan, Pemazyre is approved for the treatment of patients with unresectable biliary tract cancer (BTC) with a fibroblast growth factor receptor 2 (FGFR2) fusion gene, worsening after cancer chemotherapy.

InEurope, Pemazyre is approved for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.

Pemazyre is a potent, selective, oral inhibitor of FGFR isoforms 1, 2 and 3 which, in preclinical studies, has demonstrated selective pharmacologic activity against cancer cells with FGFR alterations.

Pemazyre is marketed byIncyteinthe United States,EuropeandJapan.

Pemazyre and the Pemazyre logo are registered trademarks ofIncyte.

* Pemazyre^®(pemigatinib) [Package Insert].Wilmington, DE:Incyte; 2020.

About NiktimvoTM (axatilimab-csfr)NiktimvoTM (axatilimab-csfr) is a first-in-class anti-CSF-1R antibody approved for use in theU.S.for the treatment of chronic graft-versus-host disease (cGVHD) after failure of at least two prior lines of systemic therapy in adult and pediatric patients weighing at least 40 kg (88.2 lbs).

In 2016, Syndax licensed exclusive worldwide rights to develop and commercialize Niktimvo from UCB. InSeptember 2021, Syndax andIncyteentered into an exclusive worldwide co-development and co-commercialization license agreement for Niktimvo in cGVHD and any future indications.

Axatilimab is being studied in frontline combination trials in chronic GVHD – a Phase 2 combination trial with ruxolitinib (NCT06388564) and a Phase 3 combination trial with steroids are expected to initiate by year end. Axatilimab is also being studied in an ongoing Phase 2 trial in patients with idiopathic pulmonary fibrosis (NCT06132256).

Niktimvo is a trademark ofIncyte.All other trademarks are the property of their respective owners.Niktimvo (axatilimab-csfr) is licensed from Syndax.

About Iclusig^®(ponatinib) tabletsIclusig^®(ponatinib) targets not only native BCR-ABL but also its isoforms that carry mutations that confer resistance to treatment, including the T315I mutation, which has been associated with resistance to other approved TKIs.

In the EU, Iclusig is approved for the treatment of adult patients with chronic phase, accelerated phase or blast phase chronic myeloid leukemia (CML) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation, or the treatment of adult patients withPhiladelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation.

Click hereto view the Iclusig EU Summary of Medicinal Product Characteristics.

Incytehas an exclusive license fromTakeda Pharmaceuticals International AGto commercialize ponatinib in theEuropean Unionand 29 other countries, includingSwitzerland,UK,Norway,Turkey,IsraelandRussia. Iclusig is marketed in theU.S.byMillennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.

AboutIncyteA global biopharmaceutical company on a mission toSolve On.,Incytefollows the science to find solutions for patients with unmet medical needs. Through the discovery, development and commercialization of proprietary therapeutics,Incytehas established a portfolio of first-in-class medicines for patients and a strong pipeline of products in Oncology and Inflammation & Autoimmunity. Headquartered inWilmington, Delaware,Incytehas operations inNorth America,EuropeandAsia.

For additional information onIncyte, please visitIncyte.comor follow us on social media:LinkedIn,X,Instagram,Facebook,YouTube.

Incyte Forward-Looking StatementsExcept for the historical information set forth herein, the matters set forth in this press release, including statements regarding the presentation of data from Incyte’s clinical development pipeline, the potential presented by that pipeline, whether or when any development compounds or combinations will be approved or commercially available for use in humans anywhere in the world outside of the already approved indications in specific regions and Incyte’s goal of improving the lives of patients, contain predictions, estimates, and other forward-looking statements.

These forward-looking statements are based on our current expectations and are subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to: unanticipated delays; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials and the ability to enroll subjects in accordance with planned schedules; determinations made by the FDA and regulatory agencies outside ofthe United States; the efficacy or safety of our products; the acceptance of our products in the marketplace; market competition; unexpected variations in the demand for our products and the products of our collaboration partners; the effects of announced or unexpected price regulation or limitations on reimbursement or coverage for our products; sales, marketing, manufacturing, and distribution requirements, including our ability to successfully commercialize and build commercial infrastructure for newly approved products and any additional new products that become approved; and other risks detailed from time to time in our reports filed with theU.S. Securities and Exchange Commission, including our annual report on Form 10-K and our quarterly report on Form 10-Q for the quarter endedSeptember 30, 2024. We disclaim any intent or obligation to update these forward-looking statements.

View source version onbusinesswire.com:https://www.businesswire.com/news/home/20241125630696/en/

Mediamedia@incyte.com

Investorsir@incyte.com

Source:Incyte

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com